Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis
Cardiology Research and Practice · 26.04.2022 · 2022 · 1-13
DOI: 10.1155/2022/8729003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiology Research and Practice, erschienen am 26.04.2022. Verfasst von Yue Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Tianjin Research Innovation Project for Postgraduate Students, Graduate Research Innovation Project of TUTCM.
Abstract (Originalsprache)
Objectives
We aimed to investigate the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor on blood lipid levels in patients with high and very-high cardiovascular risk.
Design
14 trials (n = 52,586 patients) comparing treatment with or without PCSK9 inhibitors were retrieved from PubMed and Embase updated to 1st Jun 2021. The data quality of included studies was assessed by two independent researchers using the Cochrane systematic review method. All-cause mortality, cardiovascular mortality, and changes in serum low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), apolipoprotein B (ApoB), lipoprotein (a) (LP (a)), non-high-density lipoprotein cholesterol (non-HDL-C), high-density lipoprotein cholesterol (HDL-C), and apolipoprotein A1 (ApoA1) from baseline were analyzed using Rev Man 5.1.0 software.
Results
Compared with treatments without PCSK9 inhibitor, addition of PCSK9 inhibitors (evolocumab and alirocumab) had obvious decreasing effects on the levels of LDL-C [MD = −46.86, 95% CI (−54.99 to −38.72), P < 0.00001 ], TC [MD = −31.92, 95% CI (−39.47 to −24.38), P < 0.00001 ], TG [MD = −8.13, 95% CI (−10.48 to −5.79), P < 0.00001 ], LP(a) [MD = −26.69, 95% CI (-27.93 to −25.44), P < 0.00001 ], non-HDL-C [MD = −42.86, 95% CI (−45.81 to −39.92), P < 0.00001 ], and ApoB [MD = −38.44, 95% CI (−42.23 to -34.65), P < 0.00001 ] in high CVD risk patients. Conversely, changes of HDL-C [MD = 6.27, CI (5.17 to 7.36), P < 0.00001 ] and ApoA1 [MD = 4.33, 95% CI (3.53 to 5.13), P < 0.00001 ] from baseline were significantly more in high cardiovascular disease risk patients who received PCSK9 inhibitors treatment.
Conclusion
Addition of PCSK9 inhibitors to standard therapy resulted in definite improvement in blood lipid levels compared with therapies that did not include them.
Autor:innen und Institutionen
- School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- Traditional Chinese Medicine Department, Ganzhou People's Hospital, Ganzhou, China.
- School of Nursing, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
ORCID-Profile: Yue Zhang, Yanrong Suo, Lin Yang, Xiaolu Zhang, Qun Yu, Miao Zeng, Wenlan Zhang, Xijuan Jiang, Yijing Wang
Förderung
- National Natural Science Foundation of China
- Tianjin Research Innovation Project for Postgraduate Students
- Graduate Research Innovation Project of TUTCM
- Tianjin University
Zitieren
APA
Zhang, Y., Suo, Y., Yang, L., Zhang, X., Yu, Q., Zeng, M., Zhang, W., Jiang, X., & Wang, Y. (2022). Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis. Cardiology Research and Practice, 2022, 1-13. https://doi.org/10.1155/2022/8729003
Vancouver
Zhang Y, Suo Y, Yang L, Zhang X, Yu Q, Zeng M, et al. Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis. Cardiology Research and Practice. 2022;2022:1-13. doi:10.1155/2022/8729003
BibTeX
@article{Zhang2022,
author = {Zhang, Yue and Suo, Yanrong and Yang, Lin and Zhang, Xiaolu and Yu, Qun and Zeng, Miao and Zhang, Wenlan and Jiang, Xijuan and Wang, Yijing},
title = {Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis},
journal = {Cardiology Research and Practice},
year = {2022},
volume = {2022},
pages = {1--13},
doi = {10.1155/2022/8729003}
}
EUVIMED